Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Codexis, Inc. (CDXS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
37.19+0.02 (+0.05%)
At close: 4:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close37.17
Open37.47
Bid34.50 x 800
Ask40.00 x 900
Day's Range36.51 - 38.05
52 Week Range16.55 - 42.01
Volume892,567
Avg. Volume755,449
Market Cap2.398B
Beta (5Y Monthly)1.28
PE Ratio (TTM)N/A
EPS (TTM)-0.42
Earnings DateMay 06, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.50
  • GlobeNewswire

    Codexis Presents Pre-Clinical Data Highlighting its Programs in Homocystinuria and Maple Syrup Urine Disease at ICIEM 2021

    REDWOOD CITY, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that two of the Company’s wholly owned biotherapeutic programs, CDX-6512 for the treatment of homocystinuria (HCU) and enzymes for the treatment of maple syrup urine disease (MSUD), were the subject of oral presentations at the 14th International Congress of Inborn Errors of Metabolism (ICIEM) 2021 held in Sydney, Au

  • GlobeNewswire

    Codexis to Participate in Upcoming Virtual Healthcare Conferences

    REDWOOD CITY, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Codexis, inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management will participate in three upcoming virtual investment conferences. The Piper Sandler 33rd Annual Virtual Healthcare Conference — on-demand fireside chat available beginning November 22, 2021 at 10:00 a.m. ET The Stephens Annual Investment Conference — fireside chat on November 29, 2021 at 2:00 p.m. ET

  • GlobeNewswire

    Codexis to Present Data Highlighting Two New Therapeutic Discovery Programs at the 14th International Congress of Inborn Errors of Metabolism 2021

    Company Developing Potential Treatments for Homocystinuria and Maple Syrup Urine DiseaseREDWOOD CITY, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Codexis, inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced two oral presentations highlighting its therapeutic discovery programs to develop potential treatments for homocystinuria (HCU) and maple syrup urine disease (MSUD) at the 14th International Congress of Inborn Errors of Metabolism

Advertisement
Advertisement